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Lead optimization of COX-2 inhibitor nimesulide analogs to overcome
aromatase inhibitor resistance in breast cancer cells
Bin Su, Shiuan Chen
About two thirds of breast cancers are hormone dependent,
which contain estrogen receptors (ER) and require estrogen for tu
mor growth. These patients are therefore suitable candidates for
hormonal therapy, which aims to block estrogen stimulation of
breast cancer cell growth.1 Tamoxifen has been the mainstay of
hormonal therapy in both early and advanced breast cancer pa
tients for approximately three decades. However, aromatase inhib
itors (AIs) are now proving to be more effective and to increase
survival more than antiestrogens.2–5 Over recent years AIs have be
come the ﬁrst line endocrine therapy for ER positive patients with
advanced breast cancer.6 However, after prolonged endocrine ther
apy, acquired resistance to AIs is expected to occur in a majority of
breast cancer patients.7–10 The possible resistance mechanism has
been investigated in preclinical models in our laboratory and oth
ers.8–11
The long term estrogen deprivation (LTED) system has been
used as a model for AI resistance in several laboratories, mainly
due to its lack of a hormone environment that mimics the aroma
tase inhibition effect.8,12–15 It has been reported that the activation
of the growth factor signaling pathways in LTED cell lines such as
HER2 and insulin like growth factor I receptor, which crosstalk
with the ER signaling pathway resulting in an activation of various
MAPKs and PI3K/AKT, is responsible for the cell survival and prolif
eration.8–10 Although ER is still functional in LTED cells, the trans
activation potential of ER is altered which suggests that ER
transcriptional regulation function was partially lost. LTEDaro cell
line was generated using an aromatase overexpressing MCF 7 cell
line and was suggested to be a late stage endocrine resistance
model. Nevertheless, from drug discovery point of view, LTEDaro
is a good model for the evaluation of potential compounds to over
come AI resistance.15
Nonsteroidal anti inﬂammatory drugs (NSAIDs) are beneﬁcial
in breast cancer treatment.16 It has been reported that COX 2
inhibitor nimesulide suppressed the development of 2 amino 1
methyl 6 phenylimidazo [4,5 b] pyridine (PhIP) induced mam
mary gland carcinogenesis in rats.17 Other research demonstrated
that nimesulide also suppressed aromatase activity and expression
in several breast cancer cell lines.18 Nimesulide derivatives which
do not have COX 2 inhibitory activity were more active than
nimesulide to target aromatase.19,20 Further study reveals that sev
eral nimesulide analogs were able to selectively inhibit Her2 over
expressing breast cancer cell proliferation, which suggests that
they are potentially able to overcome AI resistant breast cancer cell
growth.21 Consequent investigations demonstrated that the com
pounds induce LTEDaro cell apoptosis, which exhibited that they
can overcome AI resistance for hormone dependent breast cancer.
Because of the unique character of nimesulide derivatives, we pro
pose that the modiﬁcation of the structure might change the drug
from a COX 2 inhibitor to an anti cancer agent.20 Furthermore,
these new analogs selectively target Her2 overexpressing breast
cancer cells which makes them good candidates to overcome AI
resistance.
We try to further optimize the structure of nimesulide using the
combinatorial strategies to modify the four positions depicted in
Figure 1. Previous study demonstrated that B position as proton,
or methyl group, is the best ﬁt for the analogs to inhibit cancer cell
growth. For C position, small methyl sulfonamide or acetyl groups
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is the best ﬁt. Bulky groups will decrease the pharmacological
activity.20 For A position, methyl group substituted benzyl is better
for the activity.20 For D position, we will try pyridine group in this
study. Since nitrogen containing heterocyclics can increase aroma
tase inhibition activity, according to several other reports.22,23 In
the newly designed derivatives, we will keep B position as methyl
group and C position as methyl sulfonamide. A was modiﬁed by
using different positions and numbers of methyl group substituted
benzyls. D will be kept as pyridine or hydrophobic groups (Scheme
1). These compounds and their biological activity will enable us to
identify the key pharmacophore of this scaffold on the suppression
of LTEDaro breast cancer cell growth.
The results suggest that A position as 2,5 dimethyl or dichloro
benzyl is the best ﬁt. Compounds 33 36 and 58 61 are relatively
more active, except compounds 37 and 62 (Table 1). It seems that
D position as a picolinyl group harms the biological activity. Only
one methyl group substituted benzyl group at A position deﬁnitely
decreases the activity. Compounds 38 47 show much lower activ
ity compared with compounds 33 36. Compounds 48 57 are not
as active as compounds 33 36, which suggests that the methyl
group at 2,5 position of benzyl at A position is very critical for
the activity. Tri methyl groups clearly do not increase the activity,
which has been demonstrated by relatively low activity of com
pounds 53 57. 4 Isopropyl benzyl group or hexyl group at A posi
tion does not help the activity based on the biological results of
compounds 63 72. However, 2,5 dichloro benzyl group at A posi
tion can slightly increase the activity. Compounds 58 and 59 show
better activity compared with compounds 33 and 34.24 Overall,
nitrogen containing aromatic group at D position does not increase
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Figure 1. Chemical structure of nimesulide.
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CH3I, NaH, DMF
O2N O
N
R1
S OO
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20 R1=2,6-dimethylbenzyl (79%)
21 R1=2,4,6-trimethylbenzyl (78%)
22 R1=2,5-dichlorobenzyl (76%)
23 R1=4-isopropylbenzyl (75%)
24 R1=hexyl (91%)
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28 R1=2,6-dimethylbenzyl (82%)
29 R1=2,4,6-trimethylbenzyl (41%)
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33 R1=2,5-dimethylbenzyl; R2=cyclohexanyl (99%)
34 R1=2,5-dimethylbenzyl; R2=phenyl (97%)
35 R1=2,5-dimethylbenzyl; R2=isonicotinyl (96%)
36 R1=2,5-dimethylbenzyl; R2=nicotinyl (89%)
37 R1=2,5-dimethylbenzyl; R2=picolinyl (79%)
38 R1=2-methylbenzyl; R2=cyclohexanyl (92%)
39 R1=2-methylbenzyl; R2=phenyl (80%)
40 R1=2-methylbenzyl; R2=isonicotinyl (80%)
41 R1=2-methylbenzyl; R2=nicotinyl (87%)
42 R1=2-methylbenzyl; R2=picolinyl (81%)
43 R1=3-methylbenzyl; R2=cyclohexanyl (84%)
44 R1=3-methylbenzyl; R2=phenyl (75%)
45 R1=3-methylbenzyl; R2=isonicotinyl (74%)
46 R1=3-methylbenzyl; R2=nicotinyl (88%)
47 R1=3-methylbenzyl; R2=picolinyl (71%)
48 R1=2,6-dimethylbenzyl; R2=cyclohexanyl (90%)
49 R1=2,6-dimethylbenzyl; R2=phenyl (86%)
50 R1=2,6-dimethylbenzyl; R2=isonicotinyl (87%)
51 R1=2,6-dimethylbenzyl; R2=nicotinyl (90%)
52 R1=2,6-dimethylbenzyl; R2=picolinyl (82%)
53 R1=2,4,6-trimethylbenzyl; R2=cyclohexanyl (87%)
54 R1=2,4,6-trimethylbenzyl; R2=phenyl (84%)
55 R1=2,4,6-trimethylbenzyl; R2=isonicotinyl (68%)
56 R1=2,4,6-trimethylbenzyl; R2=nicotinyl (79%)
57 R1=2,4,6-trimethylbenzyl; R2=picolinyl (71%)
58 R1=2,5-dichlorobenzyl; R2=cyclohexanyl (93%)
59 R1=2,5-dichlorobenzyl; R2=phenyl (97%)
60 R1=2,5-dichlorobenzyl; R2=isonicotinyl (86%)
61 R1=2,5-dichlorobenzyl; R2=nicotinyl (92%)
62 R1=2,5-dichlorobenzyl; R2=picolinyl (94%)
63 R1=4-isopropylbenzyl; R2=cyclohexanyl (83%)
64 R1=4-isopropylbenzyl; R2=phenyl (86%)
65 R1=4-isopropylbenzyl; R2=isonicotinyl (79%)
66 R1=4-isopropylbenzyl; R2=nicotinyl (87%)
67 R1=4-isopropylbenzyl; R2=picolinyl (77%)
68 R1=hexyl; R2=cyclohexanyl (71%)
69 R1=hexyl; R2=phenyl (93%)
70 R1=hexyl; R2=isonicotinyl (68%)
71 R1=hexyl; R2=nicotinyl (70%)
72 R1=hexyl; R2=picolinyl (83%)
Scheme 1. Synthesis of nimesulide analogs.
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the biological activity, even though compound 36 is slightly more
potent than compounds 33 and 34.
In brief, we optimized nimesulide structure and developed sev
eral more potent analogs, such as compounds 36, 58, and 59, which
inhibit LTEDaro cell growth with IC50 of 1.69 ± 0.25 lM,
1.00 ± 0.39 lM, and 2.15 ± 0.54 lM, respectively. Compared with
nimesulide with IC50 of 173.30 ± 20.30 lM, the new derivatives
have much more potent pharmacological activity against LTEDaro
breast cancer cell growth. Structure activity relationship study
suggests that A position needs 2,5 dimethyl or dichloro benzyl
group to increase the biological activity. The exact biological mech
anism of the compound is still under investigation in our
laboratory.
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Table 1
IC50 of inhibition of LTEDaro breast cancer cells growth by compounds 33–72
Compd Inhibition of LTEDaro cell growth (IC50 lM)
Nimesulide 173.30 ± 20.30
33 2.66 ± 0.57
34 4.68 ± 0.54
35 2.37 ± 0.44
36 1.69 ± 0.25
37 174.20 ± 79.33
38 28.46 ± 5.74
39 175.60 ± 94.37
40 11.76 ± 2.34
41 71.49 ± 23.07
42 93.89 ± 30.52
43 44.18 ± 16.04
44 16.07 ± 3.65
45 16.08 ± 3.08
46 93.63 ± 59.03
47 14.89 ± 2.08
48 39.38 ± 13.88
49 16.24 ± 3.32
50 19.91 ± 5.58
51 22.53 ± 6.50
52 41.37 ± 15.70
53 18.49 ± 2.75
54 10.30 ± 3.10
55 13.18 ± 2.23
56 10.36 ± 2.42
57 51.27 ± 14.91
58 1.00 ± 0.39
59 2.15 ± 0.54
60 7.64 ± 1.67
61 14.05 ± 4.16
62 23.58 ± 8.78
63 16.06 ± 4.94
64 7.93 ± 2.85
65 11.46 ± 2.75
66 8.26 ± 3.04
67 11.41 ± 4.11
68 6.98 ± 2.93
69 12.04 ± 2.36
70 9.56 ± 1.90
71 12.07 ± 2.86
72 7.68 ± 2.45
LTEDaro cells were treated with indicated compounds at various concentrations by
triplicates for 72 h and cell viability was measured by MTT assay.25
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